Evidence map›Paper›PMID 39137882›Full record

ArticleMucosal immunology2024

RIPK3 and caspase-8 interpret cytokine signals to regulate ILC3 survival in the gut.

Ann M Joseph, Anees Ahmed, Jeremy Goc, Veronika Horn, Brooke Fiedler, Dario Garone, John B Grigg, Jazib Uddin, Fei Teng, Melanie Fritsch and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Mucosal immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. ACSS2/AATF Drives Soluble FasL-Mediated CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Ann M JosephJoan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Anees AhmedJoan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Jeremy GocJoan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Veronika HornJoan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Brooke FiedlerJoan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Dario GaroneJoan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
John B GriggJoan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Jazib UddinJoan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Fei TengJoan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Melanie FritschFaculty of Medicine and University Hospital of Cologne, Institute for Molecular Immunology, TRIO Research Center, University of Cologne, 50931 Cologne, Germany.
Eric VivierInnate Pharma, Marseille, France; Aix-Marseille University, Centre of National Scientific Research (CNRS), National Insititute of Health and Medical Research (INSERM), Centre of Immunology at Marseille-Luminy (CIML), Marseille, France; APHM, Marseille-Immunopole, University Hospital of Timone, Marseille, France.
Gregory F SonnenbergJoan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA. Electronic address: gfsonnenberg@med.cornell.edu.

Funding

Regulation of protective immunity following enteric viral infectionU01AI095608 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ARTIS, DAVID, SONNENBERG, GREGORY F · 2011 to 2025
$11.0M
Interleukin-2 regulation of mucosal inflammationR01AI145989 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SONNENBERG, GREGORY F · 2019 to 2025
$5.3M
Immune regulation of intestinal health and diseaseR01AI123368 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Gregory F Sonnenberg · 2016 to 2026
$3.6M
Innate lymphoid cell regulation of the host-microbiota interactions in cancerR01CA274534 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SONNENBERG, GREGORY F · 2022 to 2025
$3.1M
Innate immune regulation of neuroinflammationR01AI162936 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SONNENBERG, GREGORY F · 2021 to 2025
$3.1M
Novel mechanisms protecting the gut from TNFR37AI174468 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Gregory F Sonnenberg · 2023 to 2026
$2.8M
Defining a novel mechanism of mucosal healingR01AI143842 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SONNENBERG, GREGORY F · 2019 to 2023
$2.5M
Multidisciplinary Research Training in Gastroenterology and HepatologyT32DK116970 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI Randy S Longman · 2019 to 2026
$2.3M
Immunology and Microbial Pathogenesis Research Training ProgramT32AI134632 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI EHRT, SABINE, LI, MING · 2019 to 2023
$747k
ILC3 Syndecan-4 in the Regulation of Intestinal Health and InflammationF31DK134187 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI TOWERS, BROOKE ELIZABETH · 2023 to 2025
$146k
Tolerogenic and pathologic interactions between ILCs and T cells in autoimmunityF31AI138389 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI GRIGG, JOHN BENJAMIN · 2019 to 2021
$121k
NCI NIH HHS R01 CA274534NIAID NIH HHS F31 AI138389NIAID NIH HHS R01 AI123368NIAID NIH HHS R01 AI143842NIAID NIH HHS R01 AI145989NIAID NIH HHS R01 AI162936NIAID NIH HHS R37 AI174468NIAID NIH HHS T32 AI134632NIAID NIH HHS U01 AI095608NIDDK NIH HHS F31 DK134187NIDDK NIH HHS T32 DK116970
6 · The paper itself

Abstract

Group 3 innate lymphoid cells (ILC3s) are abundant in the developing or healthy intestine to critically support tissue homeostasis in response to microbial colonization. However, intestinal ILC3s are reduced during chronic infections, colorectal cancer, or inflammatory bowel disease (IBD), and the mechanisms driving these alterations remain poorly understood. Here we employed RNA sequencing of ILC3s from IBD patients and observed a significant upregulation of RIPK3, the central regulator of necroptosis, during intestinal inflammation. This was modeled in mice where we found that intestinal ILC3s express RIPK3, with conventional (c)ILC3s exhibiting high RIPK3 and low levels of pro-survival genes relative to lymphoid tissue inducer (LTi)-like ILC3s. ILC3-specific RIPK3 is promoted by gut microbiota, further upregulated following enteric infection, and dependent upon IL-23R and STAT3 signaling. However, lineage-specific deletion of RIPK3 revealed a redundant role in ILC3 survival, due to a blockade of RIPK3-mediated necroptosis by caspase 8, which was also activated in response to enteric infection. In contrast, lineage-specific deletion of caspase 8 resulted in loss of cILC3s from the healthy intestine and all ILC3 subsets during enteric infection, which increased pathogen burdens and gut inflammation. This function of caspase 8 required catalytic activity induced by TNF or TL1A and was dispensable if RIPK3 was simultaneously deleted. Caspase 8 activation and cell death were associated with increased Fas on ILC3s, and the Fas-FasL pathway was upregulated by cILC3s during enteric infection, which could restrain the abundance of intestinal ILC3s. Collectively, these data reveal that interpretation of key cytokine signals controls ILC3 survival following microbial challenge, and that an imbalance of these pathways, such as in IBD or across ILC3 subsets, provokes depletion of tissue-protective ILC3s from the inflamed intestine.

Indexed as

Caspase 8Immunity, InnateInflammatory Bowel DiseasesMice, KnockoutReceptor-Interacting Protein Serine-Threonine KinasesSignal TransductionAnimalsCell SurvivalCytokinesDisease Models, AnimalGastrointestinal MicrobiomeHumansIntestinal MucosaIntestinesLymphocytesMiceCaspase 8CytokinesReceptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, humanRipk3 protein, mouseCytokinesIBDInnate immunityInnate lymphoid cellsMucosal inflammation

Identifiers

PMID39137882
PMCPMC11637958

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.